Skip to main content
Skip to content

Duplicate Document

This document appears to be a copy. The original version is:

Ackrell Capital Chapter IV outlines U.S. Controlled Substances Act schedule definitions
Case File
kaggle-ho-024705House Oversight

Ackrell Capital Chapter IV outlines U.S. Controlled Substances Act schedule definitions

Ackrell Capital Chapter IV outlines U.S. Controlled Substances Act schedule definitions The passage merely recites public legal definitions and scheduling procedures for controlled substances, offering no specific actors, transactions, or novel allegations. It provides no actionable investigative leads. Key insights: Describes the CSA scheduling process and the roles of DEA, DHHS, and FDA.; Lists Schedule I substances, including marijuana.; Explains exclusions for hemp and non‑marijuana cannabis products.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024705
Pages
1
Persons
2
Integrity
No Hash Available

Summary

Ackrell Capital Chapter IV outlines U.S. Controlled Substances Act schedule definitions The passage merely recites public legal definitions and scheduling procedures for controlled substances, offering no specific actors, transactions, or novel allegations. It provides no actionable investigative leads. Key insights: Describes the CSA scheduling process and the roles of DEA, DHHS, and FDA.; Lists Schedule I substances, including marijuana.; Explains exclusions for hemp and non‑marijuana cannabis products.

Tags

kagglehouse-oversightcontrolled-substancescsadeadhhsfda

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
ACKRELL CAPITAL CHAPTER IV U.S. Legal Landscape with the DEA. Any person that manufactures, distributes, dispenses or otherwise possesses a controlled substance in violation of the CSA is subject to civil and criminal penalties. The CSA schedules are numbered I to V. Schedule I substances are subject to the strictest controls, and Schedule V substances are subject to the least restrictive controls. A controlled substance is listed on a particular schedule according to four factors: (i) The substance’s potential for abuse. (ii) Whether the substance has a currently accepted medical use in treatment in the United States, (iii) Whether the substance is accepted as safe to use under medical supervision. (iv) The degree of physical and psychological dependence that may result from abuse of the substance. Upon enactment in 1970, the CSA assigned each controlled substance to a specific schedule. The U.S. Congress may legislate a controlled substance’s addition to or removal from a CSA schedule. The CSA also provides a regulatory framework for a substance to be added to or removed from a schedule; such change generally involves a recommendation by the U.S. Department of Health and Human Services (DHHS) and concurrence with that recommendation by the DEA. The U.S. Food and Drug Administration, an agency of the DHHS, is charged with making certain safety-related determinations used in DHHS scheduling recommendations. Schedule I controlled substances are those found by the U.S. Congress or the DEA and the DHHS to have a high potential for abuse, to have no currently accepted medical use in treatment in the United States and to have a lack of accepted safety for use under medical supervision. Current Schedule I sub- stances include marijuana, THC, heroin, ecstasy, LSD and peyote. Unlike Schedule II through Sched- ule V controlled substances, which can be prescribed by a doctor, the CSA does not allow prescriptions to be written for Schedule I controlled substances. Marijuana Marijuana has been a Schedule I controlled substance since enactment of the CSA in 1970. The CSA defines “marijuana” as all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof: the resin extracted from any part of such plant; and every compound, manufacture, salt, deriv- ative, mixture, or preparation of such plant, its seeds or resin. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. The parts and derivatives of the cannabis plant that are excluded from the CSA definition of marijuana have industrial uses and generally contain little or no THC. Non-marijuana cannabis products—commonly known as hemp products—including rope, clothing, animal feed and soap, are not subject to control under the CSA. The CSA does not restrict such non-marijuana products © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 69

Related Documents (6)

House OversightFBI ReportNov 11, 2025

Jeffrey Epstein Child Sex Trafficking Investigation – FBI Records, Deleted Pages, Non‑Prosecution Deal, High‑Profile Connections

The compiled documents reveal a dense web of FBI case files, internal forms, and communications that reference Jeffrey Epstein’s illegal sexual activities with minors, a secret non‑prosecution agreeme FBI case number 31E‑MM‑108062 repeatedly references ‘Child Locate’ entries and deleted pages (b6, b7 Multiple internal FD‑515 forms list Jeffrey Epstein as a subject (named explicitly on 09/30/2008 e

181p
House OversightOtherNov 11, 2025

NLRB proposes and finalizes rule requiring NLRA notice postings in workplaces

The passage details routine rulemaking by the National Labor Relations Board on posting employee rights notices. It contains no allegations of misconduct, financial flows, or involvement of high‑level Executive Order 13496 (2009) mandates posting NLRA rights for federal contractors. NLRB proposed and finalized a rule making notice posting an unfair labor practice if not complied wi The rule faced

4p
House OversightOtherNov 11, 2025

Palm Beach Code Enforcement dispute over hedge compliance at Trump Properties LLC site

The passage reveals a municipal code‑enforcement conflict involving a Trump‑owned property and the town’s Architectural Commission (ARCOM). While it mentions specific dates, parties, and a $150 admini Property: 515 N. County Road, owned by Trump Properties, LLC Violation of a 1990 Architectural Commission agreement regarding hedge height (22 ft) ARCOM involvement and refusal to postpone tree plant

2p
House OversightUnknown

Mixed tabloid headlines including Prince Andrew, Bahrain protester death, and various sensational stories

Mixed tabloid headlines including Prince Andrew, Bahrain protester death, and various sensational stories The passage is a collection of unrelated tabloid headlines with no specific allegations, dates, transactions, or actionable details linking powerful actors to misconduct. It offers no concrete investigative leads. Key insights: Mentions Prince Andrew in a scandalous context but provides no details or evidence.; References a protester killed in Bahrain without further information.; Includes a variety of sensational stories unrelated to each other.

1p
House OversightUnknown

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct

NLRB Notice Draft Comments on Union Insignia, Spying, and Employer Conduct The passage is a regulatory notice from the National Labor Relations Board discussing draft language on union rights and employer conduct. It contains no specific allegations, financial flows, or links to high‑profile officials or entities. The only potential leads are generic references to comments from interest groups (Heritage Foundation, National Immigration Law Center) but they do not provide actionable evidence of misconduct. Key insights: Comments from the Heritage Foundation and National Immigration Law Center propose additions to the NLRB notice.; The Board rejects suggestions to expand the notice with specific employer retaliation examples.; Discussion of “special circumstances” for prohibiting union insignia and clarification on spying/videotaping rules.

1p
House OversightFeb 26, 2019

Cowen CBD Market Outlook Report – No Evident Investigative Leads

Cowen CBD Market Outlook Report – No Evident Investigative Leads The document is a commercial research note on CBD market size and analyst ratings, containing no references to political figures, financial misconduct, or intelligence activities. It offers no actionable investigative leads. Key insights: Provides market size estimate for U.S. CBD ($16 bn by 2025).; Cites a proprietary survey showing 7% adult usage.; Mentions analyst ratings for WEED, TLRY, TPB.

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.